Celldex Therapeutics (CLDX) has 20,754,145 shares of shorts outstanding as on August 15, 2016, with 12 days left to cover or roll them over. On Jul 29, 2016, the open interest of short positions was 21,200,305 shares. The stock has a decent trading volume of 1,719,564 shares daily. The marginal decrease in the short positions is by -2.1%, which amounts to -446,160 shares. Short positions are 21.2% of the available float. The short interest information was released on Wednesday Aug 24th after the market close.
Celldex Therapeutics (NASDAQ:CLDX): The stock opened at $3.78 on Wednesday but the bulls could not build on the opening and the stock topped out at $3.88 for the day. The stock traded down to $3.50 during the day, due to lack of any buying support eventually closed down at $3.50 with a loss of -7.41% for the day. The stock had closed at $3.78 on the previous day. The total traded volume was 2,800,978 shares.
In a related news, According to the information disclosed by the Securities and Exchange Commission in a Form 4 filing, the officer (Sr. VP & CFO) of Celldex Therapeutics, Inc., Catlin Avery W had sold 25,000 shares worth of $450,000 in a transaction dated November 23, 2015. In this transaction, 25,000 shares were sold at $18 per share.
Celldex Therapeutics, Inc. is a biopharmaceutical company focused on the development and commercialization of several immunotherapy technologies for the treatment of cancer and other difficult-to-treat diseases. The Company is engaged in the development of targeted immunotherapeutics comprised of antibodies, adjuvants and monotherapies and antibody-drug conjugates that treat cancers and other diseases. Its lead drug candidates include rindopepimut also referred to as Rintega and CDX-110 and glembatumumab vedotin also referred to as CDX-011. Its early-stage drug candidates in clinical development, includes varlilumab also referred to as CDX-1127, a fully human therapeutic monoclonal antibody for cancer indications, CDX-1401, a targeted immunotherapeutic for cancer indications and CDX-301, an immune cell mobilizing agent and dendritic cell growth factor. CDX-014 is a preclinical product under development for the treatment of cancer.